07:48 AM EDT, 06/11/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) and Sanofi ( SNY ) said Tuesday that the US Food and Drug Administration has approved Kevzara to treat patients weighing 63 kilograms or greater with active polyarticular juvenile idiopathic arthritis.

The FDA approval of the drug, also known as sarilumab, was supported by studies and data from adults with rheumatoid arthritis as well as a study of pediatric patients with polyarticular juvenile idiopathic arthritis, the companies said.

This is the third indication for Kevzara approved in the US, with the drug also approved to treat adults with moderately to severely active rheumatoid arthritis and polymyalgia rheumatica, the companies added.